Management of Renal Cell Carcinoma

Diagnosis and Initial Evaluation

For patients with suspected renal masses, contrast-enhanced CT of the chest, abdomen, and pelvis is mandatory for accurate staging and characterization of renal cell carcinoma, as recommended by the European Society for Medical Oncology 1, 2
More than 50% of RCCs are detected incidentally during abdominal imaging for unrelated conditions, with a classic triad of flank pain, gross hematuria, and palpable abdominal mass being less common but may indicate locally advanced disease, according to the American Urological Association 3, 1
Paraneoplastic syndromes such as hypercalcemia, unexplained fever, erythrocytosis, or wasting syndromes may be present in patients with RCC, as noted by the National Comprehensive Cancer Network 3, 1
Ultrasonography is typically the initial imaging modality that suggests the diagnosis, while contrast-enhanced CT of chest, abdomen, and pelvis is mandatory for accurate staging, as stated by the European Association of Urology 3, 1, 4
MRI provides additional information about local advancement and venous involvement by tumor thrombus, according to the American College of Radiology 5, 6

Clear cell RCC (ccRCC) is the most common subtype (75-80%), characterized by VHL gene inactivation, as reported by the International Society of Urological Pathology 1
Von Hippel-Lindau (VHL) disease is the most common hereditary RCC syndrome, with other syndromes including hereditary leiomyomatosis and RCC, hereditary papillary RCC, tuberous sclerosis complex, Birt-Hogg-Dubé syndrome, and SDH-deficient RCC, as described by the American Society of Clinical Oncology 3, 1, 2

Radical nephrectomy with lymph node dissection is the standard approach for locally advanced disease (T3-T4), as recommended by the European Association of Urology 7
Partial nephrectomy is the preferred surgical approach for T1a tumors to preserve renal function, according to the American Urological Association 7

Cytoreductive nephrectomy should be considered in selected patients with good performance status and limited metastatic burden, as stated by the National Comprehensive Cancer Network 7, 8
Risk stratification using the IMDC criteria is essential for treatment selection in metastatic RCC, with first-line therapy options including immune checkpoint inhibitor combinations or immune checkpoint inhibitors with tyrosine kinase inhibitors for favorable and intermediate-risk patients, as recommended by the European Society for Medical Oncology 4

For patients on systemic therapy for metastatic disease, imaging every 2-4 months is recommended, with response assessment evaluated using RECIST criteria, as stated by the American Society of Clinical Oncology 6

Hypercalcemia is a common paraneoplastic syndrome in RCC, particularly in advanced disease, and management includes hydration, bisphosphonates, and treatment of the underlying RCC, as described by the National Comprehensive Cancer Network 3, 1

For patients with suspected renal cell carcinoma, contrast‑enhanced computed tomography of the chest, abdomen, and pelvis is considered the gold‑standard imaging modality for staging, with contrast enhancement being the key criterion to identify malignant renal lesions. 9

Lumbar spine magnetic resonance imaging can incidentally reveal renal cell carcinoma, but without contrast enhancement it cannot reliably differentiate benign oncocytoma or fat‑free angiomyolipoma from malignant renal neoplasms. 9